Connor, Clark & Lunn Investment Management Ltd. Sage Therapeutics, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $20 Billion
- Q4 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 169,057 shares of SAGE stock, worth $1.23 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
169,057
Previous 65,562
157.86%
Holding current value
$1.23 Million
Previous $472,000
94.28%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding SAGE
# of Institutions
194Shares Held
45MCall Options Held
304KPut Options Held
117K-
Black Rock Inc. New York, NY5.22MShares$37.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.84MShares$35.2 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.59MShares$33.4 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.46MShares$32.4 Million0.48% of portfolio
-
Rtw Investments, LP New York, NY3MShares$21.8 Million0.27% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $432M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...